Vertex Pharmaceuticals Stock Gross Profit
| VRTX Stock | USD 397.36 0.81 0.20% |
Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Gross Profit | 8.6 B | 9 B | |
| Gross Profit Margin | 0.87 | 1.09 |
Vertex | Gross Profit |
Vertex Pharmaceuticals Company Gross Profit Analysis
Vertex Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Vertex Pharmaceuticals Gross Profit | 5.32 B |
Most of Vertex Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vertex Gross Profit Driver Correlations
Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Vertex Stock properly, considering its historical fundamentals such as Gross Profit. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Vertex Gross Profit Historical Pattern
Today, most investors in Vertex Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vertex Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's gross profit growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vertex Pharmaceuticals gross profit as a starting point in their analysis.
Vertex Pharmaceuticals Gross Profit |
| Timeline |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Vertex Pharmaceuticals reported 5.32 B of gross profit. This is 137.3% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The gross profit for all United States stocks is 80.56% higher than that of the company.
Vertex Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is currently under evaluation in gross profit category among related companies.
Vertex Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Vertex Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 92.02 B | ||||
| Shares Outstanding | 258.46 M | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 97.32 % | ||||
| Number Of Shares Shorted | 3.98 M | ||||
| Price To Earning | 24.57 X | ||||
| Price To Book | 5.83 X | ||||
| Price To Sales | 10.38 X | ||||
| Revenue | 9.84 B | ||||
| Gross Profit | 5.32 B | ||||
| EBITDA | 3.93 B | ||||
| Net Income | 3.62 B | ||||
| Cash And Equivalents | 9.77 B | ||||
| Cash Per Share | 38.06 X | ||||
| Total Debt | 808.4 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.70 X | ||||
| Book Value Per Share | 68.22 X | ||||
| Cash Flow From Operations | 3.54 B | ||||
| Short Ratio | 3.84 X | ||||
| Earnings Per Share | 13.88 X | ||||
| Price To Earnings To Growth | 0.53 X | ||||
| Target Price | 465.18 | ||||
| Number Of Employees | 5.4 K | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 102.49 B | ||||
| Total Asset | 22.73 B | ||||
| Retained Earnings | 10.14 B | ||||
| Working Capital | 10.6 B | ||||
| Current Asset | 1.41 B | ||||
| Current Liabilities | 506.35 M | ||||
| Net Asset | 22.73 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink |
Check out Vertex Pharmaceuticals Piotroski F Score and Vertex Pharmaceuticals Altman Z Score analysis. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.88 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.